Table 1 Description of 156 long-term OMT patients in Norway (NorComt study, Norway, 2012-2016)
Total N (%) | Women N (%) | Men N (%) | |
|---|---|---|---|
156 (100) | 63 (40.4) | 93 (59.6) | |
Sociodemographic variables | |||
Age (mean, SD) | 47.9 (7.1) | 46.7 (6.5) | 48.6 (7.4) |
Nordic-born | 150 (96.2) | 62 (98.4) | 88 (95.7) |
Unmarried/without partner | 133 (86.9) | 55 (88.7) | 78 (85.7) |
Employed or studying | 19 (12.2) | 5 (8.1) | 14 (15.4) |
Secondary education or higher | 80 (51.6) | 28 (45.2) | 52 (55.9) |
Treatment variables | |||
Type of OMT medication | |||
Methadone | 89 (57.0) | 38 (60.3) | 51 (54.8) |
Buprenorphine monopreparate | 42 (26.9) | 16 (25.4) | 26 (28.0) |
Buprenorphine + naloxone | 22 (14.1) | 6 (9.5) | 16 (17.2) |
Other (Morphine) | 1 (0.6) | 1 (1.6) | 0 (0.0) |
Total years in OMT (mean, SD) | 10.6 (3.7) | 11.0 (3.5) | 10.4 (3.8) |
Health and substance use | |||
SCL25 score (mean, SD) | 1.35 (0.86) | 1.54 (0.87) | 1.23 (0.83) |
Substances used, past 6 months | |||
Cannabis | 83 (53.2) | 32 (50.8) | 51 (54.8) |
Any benzodiazepines | 95 (60.6) | 41 (65.1) | 54 (58.1) |
-- Unprescribed benzodiazepines | 61 (39.1) | 27 (42.9) | 34 (36.6) |
-- Prescribed benzodiazepines | 44 (28.2) | 22 (34.3) | 22 (23.7) |
Amphetamines | 33 (21.2) | 12 (19.0) | 21 (22.6) |
Alcohol | 26 (16.7) | 7 (11.1) | 19 (20.4) |
Heroin | 26 (16.7) | 10 (15.9) | 16 (17.2) |
Unprescribed OMT medicines | 4 (2.6) | 0 (0.0) | 4 (4.3) |
Cocaine | 2 (1.3) | 0 (0.0) | 2 (2.2) |
Ecstasy | 2 (1.3) | 0 (0.0) | 1 (1.1) |
Crack | 0 (0.0) | 0 (0.0) | 0 (0.0) |
LSD | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Any nicotine use | 147 (94.2) | 60 (95.2) | 87 (93.5) |
Smoking | 142 (91.0) | 60 ( 95.2) | 82 (88.2) |
Smokeless tobacco | 20 (12.9) | 3 (4.8) | 17 (18.3) |